Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Takeo Hirose is active.

Publication


Featured researches published by Takeo Hirose.


Journal of Drug Targeting | 1995

Osteotropic Drug Delivery System (ODDS) Based on Bisphosphonic Prodrug. I: Synthesis and in Vivo Characterization of Osteotropic Carboxyfluorescein

Jiro Fujisaki; Yuji Tokunaga; Toshiya Takahashi; Takeo Hirose; Fumio Shimojo; Akira Kagayama; Takehisa Hata

An osteotropic drug delivery system (ODDS) based on a bisphosphonic prodrug was designed as a novel method for site-specific and controlled delivery of drugs to the bone. Due to the chemical adsorption of bisphosphonic promoiety to the mineral component, hydroxyapatite, a bisphosphonic prodrug is predominantly taken up into the bone. To verify the concept, bisphosphonic promoiety was chemically introduced into 6-carboxyfluorescein (CF) as a model compound and the disposition after intravenous injection was studied in rats. The bisphosphonic prodrug of CF, disodium (fluorescein-6-carbonyloxy) acetoaminomethylene bisphosphonate (CF-BP) was highly taken up to the skeleton (62.1% of dose) and the remainder was excreted into the urine (35.9% of dose). Subsequently, regeneration of CF by hydrolysis of CF-BP in the bone was observed. The microscopic observation showed that CF-BP was buried into the bone with a calcification of the bone. According to the remodeling of the bone, bisphosphonic prodrug buried was supposed to be released in the vicinity of the osteoclast or resorption surface of the bone. Thus, it is suggested that ODDS has a potential to achieve osteoclast-specific or resorption surface-specific targeting of the drugs.


Archive | 2003

Sustained release formulations containing tacrolimus

Kazunari Yamashita; Eiji Hashimoto; Yukihiro Nomura; Fumio Shimojo; Shigeki Tamura; Takeo Hirose; Satoshi Ueda; Takashi Saitoh; Rinta Ibuki; Toshio Ideno


Archive | 1998

Two surfactant-containing medicinal composition

Fumio Shimojo; Sumihisa Kimura; Takeo Hirose; Satoshi Ueda; Rinta Ibuki; Norio Ohnishi


Archive | 2001

Solid dispersion with improved absorbability

Takeo Hirose; Yoshiko Kinoshita; Fumio Shimojo; Atsuo Oike


Archive | 2003

Sustained-release pharmaceutical composition (II)

Yamashita Kazunari; Hashimoto Eiji; Nomura Yukihiro; Shimojo Fumio; Tamura Shigeki; Takeo Hirose; Satoshi Ueda; Takashi Saitoh; Rinta Ibuki; Toshio Ideno


Archive | 2001

Preparation liquide a absorbabilite amelioree

Takeo Hirose; Yoshiko Kinoshita; Fumio Shimojo; Atsuo Oike


Archive | 1999

Retardpräparat mit Makroliden wie Tacrolimus Sustained-release macrolides such as tacrolimus

Kazunari Yamashita; Eiji Hashimoto; Yukihiro Nomura; Fumio Shimojo; Shigeki Tamura; Takeo Hirose; Satoshi Ueda; Takashi Saitoh; Rinta Ibuki; Toshio Ideno


Archive | 1999

Sustained release macrolide compositions

Kazunari Yamashita; Eiji Hashimoto; Yukihiro Nomura; Fumio Shimojo; Shigeki Tamura; Takeo Hirose; Satoshi Ueda; Takashi Saitoh; Rinta Ibuki; Toshio Ideno


Archive | 1999

Retardpräparat mit Makroliden wie Tacrolimus

Eiji Hashimoto; Takeo Hirose; Rinta Ibuki; Toshio Ideno; Yukihiro Nomura; Takashi Saitoh; Fumio Shimojo; Shigeki Tamura; Satoshi Ueda; Kazunari Yamashita


Archive | 1999

Makrolid-formulierung mit verzögerter wirkstoffabgabe

Eiji Hashimoto; Takeo Hirose; Rinta Ibuki; Toshio Ideno; Yukihiro Nomura; Takashi Saitoh; Fumio Shimojo; Shigeki Tamura; Satoshi Ueda; Kazunari Yamashita

Collaboration


Dive into the Takeo Hirose's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge